Genetic Modification of Adeno-Associated Viral Vector Type 2 Capsid Enhances Gene Transfer Efficiency in Polarized Human Airway Epithelial Cells
- 1 December 2008
- journal article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 19 (12) , 1407-1414
Abstract
Cystic fibrosis (CF) is a common genetic disease characterized by defects in the expression of the CF transmembrane conductance regulator (CFTR) gene. Gene therapy offers better hope for the treatment of CF. Adeno-associated viral (AAV) vectors are capable of stable expression with low immunogenicity. Despite their potential in CF gene therapy, gene transfer efficiency by AAV is limited because of pathophysiological barriers in these patients. Although a few AAV serotypes have shown better transduction compared with the AAV2-based vectors, gene transfer efficiency in human airway epithelium has still not reached therapeutic levels. To engineer better AAV vectors for enhanced gene delivery in human airway epithelium, we developed and characterized mutant AAV vectors by genetic capsid modification, modeling the well-characterized AAV2 serotype. We genetically incorporated putative high-affinity peptide ligands to human airway epithelium on the GH loop region of AAV2 capsid protein. Six independent mutant AAV were constructed, containing peptide ligands previously reported to bind with high affinity for known and unknown receptors on human airway epithelial cells. The vectors were tested on nonairway cells and nonpolarized and polarized human airway epithelial cells for enhanced infectivity. One of the mutant vectors, with the peptide sequence THALWHT, not only showed the highest transduction in undifferentiated human airway epithelial cells but also indicated significant transduction in polarized cells. Interestingly, this modified vector was also able to infect cells independently of the heparan sulfate proteoglycan receptor. Incorporation of this ligand on other AAV serotypes, which have shown improved gene transfer efficiency in the human airway epithelium, may enhance the application of AAV vectors in CF gene therapy.Keywords
This publication has 42 references indexed in Scilit:
- Notch1 Augments Intracellular Trafficking of Adeno-Associated Virus Type 2Journal of Virology, 2007
- Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministeredProceedings of the National Academy of Sciences, 2006
- Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cellsBiochemical and Biophysical Research Communications, 2004
- Progress in the Use of Adeno-Associated Viral Vectors for Gene TherapyCells Tissues Organs, 2004
- Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway EpitheliaJournal of Virology, 2004
- Second-Strand Genome Conversion of Adeno-Associated Virus Type 2 (AAV-2) and AAV-5 Is Not Rate Limiting following Apical Infection of Polarized Human Airway EpitheliaJournal of Virology, 2003
- Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virusJournal of Clinical Investigation, 2000
- Polarity Influences the Efficiency of Recombinant Adenoassociated Virus Infection in Differentiated Airway EpitheliaHuman Gene Therapy, 1998
- A novel peptide, PLAEIDGIELTY, for the targeting of α9β1‐integrinsFEBS Letters, 1998
- A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, CaliforniaHuman Gene Therapy, 1998